IQ U.S. Mid Cap R&D Leaders ETF
MRND
MRND was delisted on the 12th of December, 2023.
0 hedge funds and large institutions have $0 invested in IQ U.S. Mid Cap R&D Leaders ETF in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $4.15M → $0 (-$4.15M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NYLIM
New York Life Investment Management
New York
|
-$4.15M |
MRND Hedge Fund Activity: Q4 2023 in Review
0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in IQ U.S. Mid Cap R&D Leaders ETF (MRND) for Q4 2023, worth a combined $0 — down 100% from $4.15M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MRND and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was New York Life Investment Management, exiting entirely with an estimated $4.15M sold.
- 0 institutional investors held IQ U.S. Mid Cap R&D Leaders ETF (MRND) as of Q4 2023, down from 1 in Q3 2023.
- Funds reported $0 of IQ U.S. Mid Cap R&D Leaders ETF stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new IQ U.S. Mid Cap R&D Leaders ETF positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest IQ U.S. Mid Cap R&D Leaders ETF seller in Q4 2023 was New York Life Investment Management, an estimated $4.15M sold.
Based on aggregated 13F filings for Q4 2023.